30 Aug, 2024 Detailed Results from the HELIOS-B Phase 3 study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy Presented at the ESC Congress 2024 and Published in The New England Journal of Medicine
body
Detailed results from the Phase 3 HELIOS-B study of vutrisiran, an RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM), were presented in a Hot Line session at the European Society of Cardiology Congress (ESC) 2024 and simultaneously published in The New England Journal of Medicine.
